Sanofi says Boehringer's ex-China CHC business is worth an estimated €1.6 billion and is a good fit with its existing business in terms of products and geographies, giving it much increased ...

Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in the past ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

The leading brands of Sanofi’s CHC business are the allergy products Allegra (2015 sales of €424m) and Nasacort (2015 sales of €122m) The deal is important for both companies, although ...

Little thought was given to media, and if it was, the advice from the environmentalist camp was to just cut back on advertising: no media, no carbon. Simple. Prasad Shridhar Ghag, global head of media ...

Sanofi’s new products like novel recombinant factor VIII therapy, Altuviiio, respiratory syncytial virus (RSV) antibody, Beyfortus (in partnership with AstraZeneca [AZN]), Pompe disease therapy ...